echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Co-develop bispecific antibodies! AbbVie's $750 million advance to Genmab

    Co-develop bispecific antibodies! AbbVie's $750 million advance to Genmab

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The two companies announced that AbbVie will make a $750 million advance payment to Genmab as part of a partnership to jointly develop and commercialize three next-generation bispecific antibodiesThe protocol includes Genmab's epcoritamab, also known as DuoBody-CD3xCD20 double resistanceIn addition to Genmab's Duo HexaBody-CD37 and DuoBody-CD3x5T4, the two companies will combine the benefits: Genmab's DuoBody technology and AbbVie's antibody-drug coupling technology to develop up to four next-generation candidate products, including solid and blood system malignanciesIn addition to the advances, Genmab will receive additional development, regulatory and sales milestone payments of up to $3.15 billion, as well as tiered royalties of 22 to 26 percent of epcoritamab's net sales outside the U.Sand JapanOf these, three existing bispecific antibody clinical development and commercialization milestones are paid up to $1.15 billion
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.